HematologyNews.net

Hematology Xagena

Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias harboring these mutations may respond to ALK inhibitors such as Crizot ...


Positive top-line results of the Kids B-LONG phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [ Coagulation Factor IX ( Recombinant ), Fc Fusion Protein ] in ...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for injection in combination with low-dose Dexamethasone versus Bortezomi ...


The FDA ( Food and Drug Administration ) has approved Farydak ( Panobinostat, previously known as LBH589 ) capsules in combination with Bortezomib ( Velcade ) and Dexamethasone for the treatment of pa ...


Vitamin D is increasingly recognized for its roles in non-skeletal disorders. Patients with sickle cell disease ( SCD ) have a high prevalence of vitamin D deficiency but data are limited with respect ...


The FDA ( Food and Drug Administration ) has granted approval of Blincyto ( Blinatumomab ) for the treatment of patients with Philadelphia chromosome-negative ( Ph- ) relapsed or refractory B-cell pre ...


Data from the largest clinical trial of myelofibrosis patients treated with Ruxolitinib ( Jakavi ) were presented at 56th Annual Meeting of the American Society of Hematology ( ASH ) in San Francisco ...


The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. Researchers hypothesized that such mutations would be detect ...


Final data from a phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events ( VTE ) in patients treated with ISIS-FXI Rx undergoing total knee replacement surgery, o ...


The results from the STRATUS trial ( MM-010 ), a single-arm phase IIIb study of Pomalidomide ( Imnovid, Pomalyst ) plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma ...


Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...


Positive results from a cohort of patients in its ongoing phase 1b trial ( CheckMate-039 ) which evaluated PD-1 immune checkpoint inhibitor, Nivolumab ( Opdivo), in patients with relapsed or refractor ...


Venous and arterial thromboses have been regarded for many years as two different diseases requiring anticoagulant or antiplatelet treatment, respectively. Platelets have a role in venous thromboe ...


Chronic ophthalmological complications of SCD include proliferative sickle retinopathy ( PSR ) and vitreous hemorrhage. They occur in up to 50% of individuals with SCD, and are found more frequently ...


Positive results of the Kids A-LONG phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in childr ...


The FDA ( Food and Drug Administration ) has approved a Supplemental New Drug Application ( sNDA ) for Eliquis ( Apixaban ) for the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( P ...


Chronic kidney disease ( CKD ) is defined as either having a glomerular filtration rate ( GFR ) of less than 60 mL/min/1.73 mL for more than 3 months with or without kidney damage or having evidence o ...


Ultrasound-guided foam sclerotherapy and endovenous laser ablation are widely used alternatives to surgery for the treatment of varicose veins, but their comparative effectiveness and safety remain un ...


Data from FIRST, an open-label phase III randomized study of continuous Lenalidomide ( Revlimid ) in combination with Dexamethasone in patients newly diagnosed with multiple myeloma ( NDMM ) who are n ...


Pulmonary hypertension ( PH ) is defined as an elevation of the resting mean pulmonary arterial pressure ( greater than or equal to 25 mmHg ) as determined by right heart catheterization ( RHC ). Th ...


Leg ulcers are a common complication of sickle cell disease ( SCD ) in general and sickle-cell anaemia ( SCA ) in particular. Leg ulceration was reported in all of the first four people with sickle ce ...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration or adverse cytogenetics have poor outcomes. Researchers have evaluated th ...


Avascular necrosis ( AVN, also known as aseptic necrosis, osteonecrosis, or ischemic necrosis ) is bone death due to compromised blood supply. Necrosis can occur when capillaries are occluded by sic ...


The Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Eltrombopag in patients with severe aplastic anaemia who have had an insuff ...


In sickle cell disease ( SCD ), pain is considered chronic if it lasts more than 3 months. People with sickle cell disease experience both nociceptive and neuropathic pain. Nociceptive pain is a hallm ...


The Pharmacovigilance Risk Assessment Committee ( PRAC ) of the European Medicines Agency ( EMA ) has concluded its review of Iclusig ( Ponatinib ) under the Article 20 referral procedure and has reco ...


Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia ( AML ) aged 65 or older and ineligible f ...


Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma ( DLBCL ) given a regimen of Rituximab ( MabThera, Rituxan ), Cyclophosphamide ( Endoxan ), Doxorubicin ( Adriamycin ), Vincr ...


Intravenous Rituximab ( MabThera, Rituxan ) is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent Rituximab serum concentrations might improve conveni ...


Acute graft-versus-host disease ( GVHD ) remains a barrier to more widespread application of allogeneic haemopoietic stem-cell transplantation. Vorinostat ( Zolinza ) is an inhibitor of histone deac ...


Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints migh ...


Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in eld ...


Lenalidomide ( Revlimid ) has been linked to second primary malignancies in myeloma. Researchers have aimed to pool and analyse available data to compare the incidence of second primary malignancies i ...


Beta-thalassemias are characterized by ineffective red blood cell ( RBC ) production, leading to anemia, iron overload, and organ failure. As current treatment options for beta-thalassemia are limited ...


In acute lymphoblastic leukemia ( ALL ) response to therapy is usually measured by microscopic analysis of the bone marrow. The detection level for leukemic cells by this method is 5%. With molecular ...


A phase-I study for patients with chronic lymphocytic leukaemia has shown promising results. Chronic lymphocytic leukaemia ( CLL ) is the most common leukemia in adults in the Western world and is dia ...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


The results of phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera were presented at the 50th Annual Meeting of the American Society of Clinical Oncology ( ASCO ). ...


Phosphatidylinositol-3-kinase delta ( PI3Kδ ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 ...


The monoclonal anti-CD20 antibody Rituximab ( MabThera, Rituxan ), combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreate ...


Acute lymphoblastic leukemia ( ALL ) is a rare type of blood cancer which is mainly treated by intensive chemotherapy. If the disease is resistant to initial treatment or reoccurs ( relapse ) the cha ...


Patients with relapsed chronic lymphocytic leukemia ( CLL ) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with accep ...


Immobilization of the lower leg is associated with venous thromboembolism ( VTE ). Low molecular weight Heparin ( LMWH ) is an anticoagulant treatment which might be used in adult patients with lower- ...


The combination of lenalidomide ( Revlimid ) and Rituximab ( Rituxan ) has shown synergistic activity in chronic lymphocytic leukemia ( CLL ) preclinical models. In a CLL Research Consortium phase I ...


Updated interim results of a phase 2 study ( Study 102 ) evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase ( Syk ), for the treatment of patients with relapsed chronic ly ...


Early results of a randomized phase III GITMO/FIL study comparing CHOP-R vs. R-HDS + ASCT as primary treatment in 134 FL pts, aged less than or equal to 60 yrs with aaIPI greater than 1/IIL score grea ...


The results from PANORAMA-1 ( PANobinostat ORAl in Multiple MyelomA ) trial were presented at ASCO meeting, showing a 37% improvement in progression-free survival ( PFS ) when using the investigationa ...


The FDA ( Food and Drug Administration ) has approved a Supplemental Biologic License Application ( sBLA ) for the use of Arzerra ( Ofatumumab ), a CD20-directed cytolytic monoclonal antibody, in comb ...


A group of researchers at the Institute for Research in Immunology and Cancer ( IRIC ) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is re ...


The Food and Drug Administration ( FDA ) has expanded the approved use of Imbruvica ( Ibrutinib ) for chronic lymphocytic leukemia ( CLL ) patients who have received at least one previous therapy.Chro ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati